Verve Therapeutics, Inc.

Some of the best links we picked up around the internet

CMN Weekly (28 March 2025) - Your Weekly CRISPR...

CMN Weekly

Mar. 28, 2025

Some of the best links we picked up around the internet

CMN Weekly (8 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 8, 2024

Some of the best links we picked up around the internet

CMN Weekly (7 June 2024) - Your Weekly CRISPR...

CMN Weekly

Jun. 7, 2024

Some of the best links we picked up around the internet

CMN Weekly (24 May 2024) - Your Weekly CRISPR...

CMN Weekly

May. 24, 2024

Some of the best links we picked up around the internet

CMN Weekly (10 May 2024) - Your Weekly CRISPR...

CMN Weekly

May. 10, 2024

Some of the best links we picked up around the internet

Gene-Editing Clinical Trial Updates - What's...

CMN Clinical

Apr. 10, 2024

Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

CMN Weekly (1 March 2024) - Your Weekly CRISPR...

CMN Weekly

Mar. 1, 2024

Some of the best links we picked up around the internet

Verve Therapeutics, Inc.

Refractory Hypercholesterolemia, NCT06451770
Sponsors:
Verve Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Familial Hypercholesterolemia, HeFH, or Premature Coronary Artery Disease, CAD, (NCT06164730)
Sponsors:
Verve Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Familial Hypercholesterolemia, FH, (NCT06112327)
Sponsors:
Verve Therapeutics, Inc.

IND Enabling

Phase I

Phase II

Phase III

Familial Hypercholesterolemia, FH, (NCT05398029)
Sponsors:
Verve Therapeutics, Inc.,

IND Enabling

Phase I

Phase II

Phase III